Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YZJ
|
|||
| Former ID |
DIB004033
|
|||
| Drug Name |
ALO-02
|
|||
| Synonyms |
ALO-02 Oxycodone-naltrexone core
Click to Show/Hide
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 3 | [1] | |
| Company |
Elite Pharmaceuticals; pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor (OPR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Pfizer. | |||
| REF 2 | Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005 Jun;6(6):392-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.